Sign up
Pharma Capital

Canopy Growth, Canopy Rivers to collaborate with LiveWell Foods on giant cannabis projects

Livewell has a full seed-to-sale solution and has two large greenhouse projects in development
1522934974_SupremePharma1.jpg
Pictured is a cannabis greenhouse

The Canadian weed industry was back in the spotlight Thursday as Canopy Growth Corp (TSX:WEED), Canopy Rivers and LiveWell Foods Canada Inc are to collaborate to commercialise Livewell's two large scale pot projects in Ontario and Quebec.

LiveWell is a vertically integrated cannabis company with a full seed-to-sale solution, including two large greenhouse projects in development totalling over 1.5mln sq ft.

READ: Canopy Growth and Delta 9 given green light to open cannabis retail stores in Manitoba

The private firm has established partnerships with leading names in the sector and also distributes retail and bulk hemp products under the O-Hemp brand and plans to distribute cannabis edibles and infused products.

Canopy's team will provide LiveWell with high-quality genetics for initial cultivation, access to trained personnel for guidance/support, and other strategic and financial support .

"This new partnership represents further validation that Canopy is the platform of choice in the cannabis sector," said Bruce Linton, Canopy Growth chief executive and chairman.

"Canopy has an unmatched ability to collaborate with partners given our breadth of operational knowledge, technology, investment capital, and cultivation expertise."

LiveWell has received an initial purchase agreement from Canopy, for cannabis production at the Ottawa project.

LiveWell also has the option to draw on up to $20,000,000 of debt financing from Canopy Rivers (subject to certain milestones) to support the firm's continued growth.

Canopy Growth shares added 0.22% Thursday to stand at C$27.70.

Giles_55af4ddca6481.jpg


Register here to be notified of future Company articles
View full profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.